April 15th, 2010

Biothera raises $3.5M, looking for more

By

Biothera has raised $3.5 million and the company doesn’t want to stop there, as it aims to push that total to $25 million, according to a regulatory filing…

 

Biothera is in the midst of Phase 2 trials of its drug, Immprime PGG, with patients suffering from lung cancer, said David Walsh, vice president of communications. It’s completed early trials of the drug with colorectal cancer patients. The company also plans to conduct two trials in collaboration with the Mayo Clinic–one for melanoma, a type of skin cancer, and the other for chronic lymphocytic leukemia, a cancer of the blood and bone marrow.

 

MedCity News, by Brandon Glenn, 4/2010

Tags: Biothera, Business Relations, Cancer, Cancer

Contact Us · Privacy Policy